Pharmacometabolomics reveals urinary diacetylspermine as a biomarker of doxorubicin effectiveness in triple negative breast cancer
Open Access
- 7 October 2022
- journal article
- research article
- Published by Springer Nature in npj Precision Oncology
- Vol. 6 (1) , 1-11
Abstract
Triple-negative breast cancer (TNBC) patients receive chemotherapy treatment, including doxorubicin, due to the lack of targeted therapies. Drug resistance is a major cause of treatment failure in TNBC and therefore, there is a need to identify biomarkers that determine effective drug response. A pharmacometabolomics study was performed using doxorubicin sensitive and resistant TNBC patient-derived xenograft (PDX) models to detect urinary metabolic biomarkers of treatment effectiveness. Evaluation of metabolite production was assessed by directly studying tumor levels in TNBC-PDX mice and human subjects. Metabolic flux leading to biomarker production was determined using stable isotope-labeled tracers in TNBC-PDX ex vivo tissue slices. Findings were validated in 12-h urine samples from control (n = 200), ER+/PR+ (n = 200), ER+/PR+/HER2+ (n = 36), HER2+ (n = 81) and TNBC (n = 200) subjects. Diacetylspermine was identified as a urine metabolite that robustly changed in response to effective doxorubicin treatment, which persisted after the final dose. Urine diacetylspermine was produced by the tumor and correlated with tumor volume. Ex vivo tumor slices revealed that doxorubicin directly increases diacetylspermine production by increasing tumor spermidine/spermine N1-acetyltransferase 1 expression and activity, which was corroborated by elevated polyamine flux. In breast cancer patients, tumor diacetylspermine was elevated compared to matched non-cancerous tissue and increased in HER2+ and TNBC compared to ER+ subtypes. Urine diacetylspermine was associated with breast cancer tumor volume and poor tumor grade. This study describes a pharmacometabolomics strategy for identifying cancer metabolic biomarkers that indicate drug response. Our findings characterize urine diacetylspermine as a non-invasive biomarker of doxorubicin effectiveness in TNBC.Keywords
All Related Versions
Funding Information
- National Cancer Institute Intramural Research Program
This publication has 36 references indexed in Scilit:
- Excretion of N 1 , N 12 -diacetylspermine in the urine of healthy individualsAnnals of Clinical Biochemistry: International Journal of Laboratory Medicine, 2013
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortalScience Signaling, 2013
- Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer SubtypesJournal of Clinical Oncology, 2012
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Pharmaco‐metabolomics: An emerging “omics” tool for the personalization of anticancer treatments and identification of new valuable therapeutic targetsJournal of Cellular Physiology, 2011
- Comprehensive Profiling and Quantitation of Amine Group Containing MetabolitesAnalytical Chemistry, 2011
- Spermidine/spermine-N1-acetyltransferase: a key metabolic regulatorAmerican Journal of Physiology-Endocrinology and Metabolism, 2008
- Established breast cancer risk factors by clinically important tumour characteristicsBritish Journal of Cancer, 2006
- Interaction of N1,N12-Diacetylspermine with Polyamine Transport Systems of Polarized Porcine Renal Cell Line LLC-PK1The Journal of Biochemistry, 2005
- N 1,N12-Diacetylspermine as a Sensitive and Specific Novel Marker for Early- and Late-Stage Colorectal and Breast CancersClinical Cancer Research, 2005